Thanks to such progression in patient management with the development of this next-generation technology, physicians can offer satisfactory solutions to patients suffering from at-risk NASH ." GENFIT continues to explore the possibility of obtaining regulatory approval and CE Certificates of Conformity, alone or with a development and commercial partner, to release an IVD test powered by NIS2+™ technology on the US and European markets. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.